Drug Sensitivity Prediction Models Reveal a Link between DNA Repair Defects and Poor Prognosis in HNSCC.
Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
Cell Line, Tumor
Chemoradiotherapy
/ methods
Cisplatin
/ pharmacology
DNA Damage
/ drug effects
DNA Repair
/ drug effects
Gene Expression
/ drug effects
Head and Neck Neoplasms
/ drug therapy
Humans
Mutation
/ drug effects
Phenotype
Prognosis
Rad52 DNA Repair and Recombination Protein
/ genetics
Retrospective Studies
Squamous Cell Carcinoma of Head and Neck
/ drug therapy
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
01 Nov 2019
01 Nov 2019
Historique:
received:
07
11
2018
revised:
16
05
2019
accepted:
05
09
2019
pubmed:
14
9
2019
medline:
29
5
2020
entrez:
14
9
2019
Statut:
ppublish
Résumé
Head and neck squamous cell carcinoma (HNSCC) is characterized by the frequent manifestation of DNA crosslink repair defects. We established novel expression-based DNA repair defect markers to determine the clinical impact of such repair defects. Using hypersensitivity to the DNA crosslinking agents, mitomycin C and olaparib, as proxies for functional DNA repair defects in a panel of 25 HNSCC cell lines, we applied machine learning to define gene expression models that predict repair defects. The expression profiles established predicted hypersensitivity to DNA-damaging agents and were associated with mutations in crosslink repair genes, as well as downregulation of DNA damage response and repair genes, in two independent datasets. The prognostic value of the repair defect prediction profiles was assessed in two retrospective cohorts with a total of 180 patients with advanced HPV-negative HNSCC, who were treated with cisplatin-based chemoradiotherapy. DNA repair defects, as predicted by the profiles, were associated with poor outcome in both patient cohorts. The poor prognosis association was particularly strong in normoxic tumor samples and was linked to an increased risk of distant metastasis.
Identifiants
pubmed: 31515237
pii: 0008-5472.CAN-18-3388
doi: 10.1158/0008-5472.CAN-18-3388
doi:
Substances chimiques
Antineoplastic Agents
0
Rad52 DNA Repair and Recombination Protein
0
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5597-5611Informations de copyright
©2019 American Association for Cancer Research.